Beckman Coulter, Inc., an established manufacturer with a proven track record in providing best-in-class laboratory-solutions, has announced that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics. The transaction is expected to close in Q1 2015. The agreement is subject to applicable regulatory approvals and other customary closing conditions.
Blending the accuracy of the MicroScan® system and preanalytical and analytical automation, Siemens provides a vast collection of Microbiology Systems, MicroScan Panels and Microbiology IT Systems designed to enhance lab productivity. Siemens’ microbiology business operates with an installed base of over 6,000 instruments globally, and is part of its diagnostics division, which finished last year with $5.332 billion (€3.942 billion) in revenue.
On the acquisition of the Siemens clinical microbiology business, Beckman Coulter Diagnostics President Arnd Kaldowski says, “The clinical microbiology business will be an excellent complement to Beckman Coulter’s Diagnostics business, with a strong reputation and market position”.
An indirect, wholly owned subsidiary of Danaher, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories in six continents. Reliable lab equipment suppliers offer quality hematology analyzers, flow cytometers and coagulation analyzers manufactured by Beckman Coulter, Inc.
It is expected that adding on differentiated analytical systems and menu solutions from Siemens to its existing products and services will offer Beckman Coulter the chance to improve its offerings for laboratories and enhance patient care, while driving continued growth.